Benitec Biopharma: OPMD Program Continues To Advance With Catalysts

Group 1 - Benitec Biopharma Inc. (NASDAQ: BNTC) reported positive results from its phase 1b/2a clinical study using BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD) [1] - The positive interim results were reported at two time points during the study [1] Group 2 - The article is authored by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace [1] - The Biotech Analysis Central service offers a deep-dive analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [1]